Effect of interleukin-13 or tumor necrosis factor-alpha on eosinophil adhesion to endothelial cells under physiological flow conditions.
BACKGROUND
We examined the mechanisms used by eosinophils to accumulate on IL-13- or TNF-alpha-stimulated human umbilical vein endothelial cells (HUVECs) under flow conditions.


METHODS
HUVECs were treated for 1, 3, 6, 18 and 24 h with IL-13 or TNF-alpha (1-100 ng/ml). Human eosinophils were infused at physiologic flow rates (0.5 dyn/cm(2)) for 10 min, and attached eosinophils were counted.


RESULTS
Under these flow conditions, eosinophils accumulated efficiently on IL-13-stimulated (109 +/- 18 cells/field) or TNF-alpha-stimulated (96 +/- 27 cells/field) HUVECs in a concentration-dependent manner. Eosinophil accumulation on IL-13-activated HUVECs was first observed at 3 h and reached a maximum at 24 h. On the other hand, the levels of eosinophils accumulating on TNF-alpha-activated HUVECs were the same at all time points (1, 3, 6, 18 and 24 h). Anti-alpha4 integrin mAb inhibited eosinophil accumulation on both IL-13- and TNF-alpha-activated HUVECs.


CONCLUSIONS
Eosinophil accumulation on HUVECs under physiologic flow conditions is differentially regulated by IL-13 and TNF-alpha.
Tachimoto
Hiroshi
H
Department of Allergy, Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, National Hospital Organization, Sagamihara, Japan. tachimoto@sagamihara-hosp.gr.jp
Ebisawa
Motohiro
M
D018821:CD18 Antigens / Q000502:physiology; D002448:Cell Adhesion / Q000187:drug effects*; D002478:Cells, Cultured / Q000166:cytology / Q000187:drug effects; D019040:E-Selectin / Q000032:analysis / Q000096:biosynthesis / Q000235:genetics; D042783:Endothelial Cells / Q000166:cytology / Q000187:drug effects*; D004804:Eosinophils / Q000166:cytology / Q000187:drug effects*; D018056:Hemorheology; D006801:Humans; D039441:Integrin alpha4 / Q000502:physiology; D018799:Intercellular Adhesion Molecule-1 / Q000032:analysis / Q000096:biosynthesis / Q000235:genetics; D018793:Interleukin-13 / Q000494:pharmacology*; D019041:L-Selectin / Q000502:physiology; D008562:Membrane Glycoproteins / Q000037:antagonists & inhibitors / Q000502:physiology; D019007:P-Selectin / Q000032:analysis / Q000096:biosynthesis / Q000235:genetics; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology*; D014471:Umbilical Veins; D019010:Vascular Cell Adhesion Molecule-1 / Q000032:analysis / Q000096:biosynthesis / Q000235:genetics; D014743:Videotape Recording
D018821:CD18 Antigens; D019040:E-Selectin; D018793:Interleukin-13; D008562:Membrane Glycoproteins; D019007:P-Selectin; C084882:P-selectin ligand protein; D014409:Tumor Necrosis Factor-alpha; D019010:Vascular Cell Adhesion Molecule-1; D018799:Intercellular Adhesion Molecule-1; D019041:L-Selectin; D039441:Integrin alpha4